Adhesion glycoprotein CD44 functions as an upstream regulator of a network connecting ERK, AKT and Hippo-YAP pathways in cancer progression

Oncotarget

Volumn 6, Issue 5, 2015, Pages 2951-2965

  Yu, Shiyi ^a   Cai, Xiuxiu ^a   Wu, Chenxi ^a   Wu, Lele ^a   Wang, Yuzhi ^a   Liu, Yan ^a   Yu, Zhenghong ^b   Qin, Sheng ^c   Ma, Fei ^c   Thiery, Jean Paul ^d,e,f   Chen, Liming ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

^c NANJING NORMAL UNIVERSITY   (China)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

CD44; Oncogenesis; Signaling network

Indexed keywords

HERMES ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ONCOPROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; CD44 PROTEIN, HUMAN; HIPPO PROTEIN, HUMAN; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

AKT PATHWAY; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER STEM CELL; CELL CONTACT; CELL CYCLE PROGRESSION; CELL DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; ERK PATHWAY; FEMALE; GENE EXPRESSION; HIPPO YAP PATHWAY; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL CYCLE CHECKPOINT; DRUG EFFECTS; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TIME; TUMOR CELL LINE; TUMOR VOLUME;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, CD44; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASTIC STEM CELLS; PHOSPHOPROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN;

EID: 84923297585     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3095     Document Type: Article

References (95)

1. Merlo LM, Pepper JW, Reid BJ and Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer. 2006; 6(12):924-935.
2. Greaves M and Maley CC. Clonal evolution in cancer. Nature. 2012; 481(7381):306-313.
3. Blanpain C. Tracing the cellular origin of cancer. Nat Cell Biol. 2013; 15(2):126-134.
4. Roberts PJ and Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007; 26(22):3291-3310.
5. Kohno M and Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med. 2006; 38(3):200-211.
6. Vivanco I and Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501.
7. Craven RJ, Lightfoot H and Cance WG. A decade of tyrosine kinases: from gene discovery to therapeutics. Surg Oncol. 2003; 12(1):39-49.
8. Harvey KF, Zhang X and Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer. 2013; 13(4):246-257.
9. Pan D. The hippo signaling pathway in development and cancer. Dev Cell. 2010; 19(4):491-505.
10. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A and Pan D. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007; 130(6):1120-1133.
11. Johnson R and Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov. 2014; 13(1):63-79.
12. Schlegelmilch K, Mohseni M, Kirak O, Pruszak J, Rodriguez JR, Zhou D, Kreger BT, Vasioukhin V, Avruch J, Brummelkamp TR and Camargo FD. Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell. 2011; 144(5):782-795.
13. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS and Haber DA. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A. 2006; 103(33):12405-12410.
14. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, Li L, Zheng P, Ye K, Chinnaiyan A, Halder G, Lai ZC and Guan KL. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007; 21(21):2747-2761.
15. Dent P. Crosstalk between ERK, AKT, and cell survival. Cancer Biol Ther. 2014; 15(3):245-246.
16. Basu S, Totty NF, Irwin MS, Sudol M and Downward J. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell. 2003; 11(1):11-23.
17. Hermeking H. The 14-3-3 cancer connection. Nat Rev Cancer. 2003; 3(12):931-943.
18. Csibi A and Blenis J. Hippo-YAP and mTOR pathways collaborate to regulate organ size. Nat Cell Biol. 2012; 14(12):1244-1245.
19. Zhao B, Li L, Wang L, Wang CY, Yu J and Guan KL. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 2012; 26(1):54-68.
20. Zhang J, Ji JY, Yu M, Overholtzer M, Smolen GA, Wang R, Brugge JS, Dyson NJ and Haber DA. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol. 2009; 11(12):1444-1450.
21. Eagle H and Levine EM. Growth regulatory effects of cellular interaction. Nature. 1967; 213(5081):1102-1106.
22. Naor D, Sionov RV and Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res. 1997; 71:241-319.
23. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-3988.
24. Haraguchi N, Ohkuma M, Sakashita H, Matsuzaki S, Tanaka F, Mimori K, Kamohara Y, Inoue H and Mori M. CD133+CD44+ population efficiently enriches colon cancer initiating cells. Ann Surg Oncol. 2008; 15(10):2927-2933.
25. Lee CJ, Dosch J and Simeone DM. Pancreatic cancer stem cells. J Clin Oncol. 2008; 26(17):2806-2812.
26. Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD, Fink LM, Ma Y and Wong MP. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One. 2010; 5(11):e14062.
27. Ailles L and Prince M. Cancer stem cells in head and neck squamous cell carcinoma. Methods Mol Biol. 2009; 568:175-193.
28. Yang YM and Chang JW. Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest. 2008; 26(7):725-733.
29. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH and Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008; 68(11):4311-4320.
30. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, Schultz PG and Reddy VA. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A. 2009; 106(1):268-273.
31. Feng D, Peng C, Li C, Zhou Y, Li M, Ling B, Wei H and Tian Z. Identification and characterization of cancer stemlike cells from primary carcinoma of the cervix uteri. Oncol Rep. 2009; 22(5):1129-1134.
32. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y and Wang TC. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 2009; 27(5):1006-1020.
33. Zhu Z, Hao X, Yan M, Yao M, Ge C, Gu J and Li J. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer. 2010; 126(9):2067-2078.
34. Su J, Xu XH, Huang Q, Lu MQ, Li DJ, Xue F, Yi F, Ren JH and Wu YP. Identification of cancer stem-like CD44+ cells in human nasopharyngeal carcinoma cell line. Arch Med Res. 2011; 42(1):15-21.
35. Dou J, Pan M, Wen P, Li Y, Tang Q, Chu L, Zhao F, Jiang C, Hu W, Hu K and Gu N. Isolation and identification of cancer stem-like cells from murine melanoma cell lines. Cell Mol Immunol. 2007; 4(6):467-472.
36. Louderbough JM and Schroeder JA. Understanding the dual nature of CD44 in breast cancer progression. Mol Cancer Res. 2011; 9(12):1573-1586.
37. Ponta H, Sherman L and Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003; 4(1):33-45.
38. Bourguignon LY, Singleton PA, Zhu H and Diedrich F. Hyaluronan-mediated CD44 interaction with RhoGEF and Rho kinase promotes Grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem. 2003; 278(32):29420-29434.
39. Cordo Russo RI, Garcia MG, Alaniz L, Blanco G, Alvarez E and Hajos SE. Hyaluronan oligosaccharides sensitize lymphoma resistant cell lines to vincristine by modulating P-glycoprotein activity and PI3K/Akt pathway. Int J Cancer. 2008; 122(5):1012-1018.
40. Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA and Kuo PC. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther. 2009; 17(1):153-161.
41. Urakawa H, Nishida Y, Wasa J, Arai E, Zhuo L, Kimata K, Kozawa E, Futamura N and Ishiguro N. Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo. Int J Cancer. 2012; 130(2):454-466.
42. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J and Cheng C. CD44 splice isoform switching in human and mouse epithelium is essential for epithelialmesenchymal transition and breast cancer progression. J Clin Invest. 2011; 121(3):1064-1074.
43. Orian-Rousseau V, Chen L, Sleeman JP, Herrlich P and Ponta H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 2002; 16(23):3074-3086.
44. Fang XJ, Xu WL, Gong JL, Chen C, Fang LL and Chen QY. [CD44 variant increases the invasive ability of human breast cancer cell line MCF-7 cells]. Zhonghua Zhong Liu Za Zhi. 2010; 32(1):22-28.
45. Xu Y, Stamenkovic I and Yu Q. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res. 2010; 70(6):2455-2464.
46. Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, Konig H, Weg-Remers S and Ponta H. CD44 acts both as a growth-and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci. 2000; 910:106-118; discussion 118-120.
47. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1):57-70.
48. Haynes BF, Telen MJ, Hale LP and Denning SM. CD44--a molecule involved in leukocyte adherence and T-cell activation. Immunol Today. 1989; 10(12):423-428.
49. Suhara T, Kim HS, Kirshenbaum LA and Walsh K. Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Aktmediated Fas ligand regulation. Mol Cell Biol. 2002; 22(2):680-691.
50. Uriarte SM, Joshi-Barve S, Song Z, Sahoo R, Gobejishvili L, Jala VR, Haribabu B, McClain C and Barve S. Akt inhibition upregulates FasL, downregulates c-FLIPs and induces caspase-8-dependent cell death in Jurkat T lymphocytes. Cell Death Differ. 2005; 12(3):233-242.
51. Imai Y, Takahashi A, Hanyu A, Hori S, Sato S, Naka K, Hirao A, Ohtani N and Hara E. Crosstalk between the Rb pathway and AKT signaling forms a quiescence-senescence switch. Cell Rep. 2014; 7(1):194-207.
52. Heinonen H, Nieminen A, Saarela M, Kallioniemi A, Klefstrom J, Hautaniemi S and Monni O. Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer. BMC Genomics. 2008; 9:348.
53. Morrison H, Sherman LS, Legg J, Banine F, Isacke C, Haipek CA, Gutmann DH, Ponta H and Herrlich P. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 2001; 15(8):968-980.
54. Hamaratoglu F, Willecke M, Kango-Singh M, Nolo R, Hyun E, Tao C, Jafar-Nejad H and Halder G. The tumoursuppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol. 2006; 8(1):27-36.
55. Negi LM, Talegaonkar S, Jaggi M, Ahmad FJ, Iqbal Z and Khar RK. Role of CD44 in tumour progression and strategies for targeting. J Drug Target. 2012; 20(7):561-573.
56. Yu Q, Toole BP and Stamenkovic I. Induction of apoptosis of metastatic mammary carcinoma cells in vivo by disruption of tumor cell surface CD44 function. J Exp Med. 1997; 186(12):1985-1996.
57. Jaggupilli A and Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol. 2012; 2012:708036.
58. Pastrana E, Silva-Vargas V and Doetsch F. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell. 2011; 8(5):486-498.
59. Holliday DL and Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011; 13(4):215.
60. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW and Daley GQ. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008; 451(7175):141-146.
61. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K and Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5):861-872.
62. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin, II and Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007; 318(5858):1917-1920.
63. Yu F, Li J, Chen H, Fu J, Ray S, Huang S, Zheng H and Ai W. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene. 2011; 30(18):2161-2172.
64. Leng Z, Tao K, Xia Q, Tan J, Yue Z, Chen J, Xi H, Li J and Zheng H. Kruppel-like factor 4 acts as an oncogene in colon cancer stem cell-enriched spheroid cells. PLoS One. 2013; 8(2):e56082.
65. Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J and Klein B. Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun. 2009; 383(2):157-162.
66. Katz JP, Perreault N, Goldstein BG, Actman L, McNally SR, Silberg DG, Furth EE and Kaestner KH. Loss of Klf4 in mice causes altered proliferation and differentiation and precancerous changes in the adult stomach. Gastroenterology. 2005; 128(4):935-945.
67. Kumar M, Nagpal R, Hemalatha R, Verma V, Kumar A, Singh S, Marotta F, Jain S and Yadav H. Targeted cancer therapies: the future of cancer treatment. Acta Biomed. 2012; 83(3):220-233.
68. Altomare DA and Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005; 24(50):7455-7464.
69. Zimmermann S and Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science. 1999; 286(5445):1741-1744.
70. Will M, Qin AC, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, Huang X, Monian P, Jiang X, de Stanchina E, Baselga J, Liu N, Chandarlapaty S and Rosen N. Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov. 2014; 4(3):334-347.
71. Toulany M, Minjgee M, Saki M, Holler M, Meier F, Eicheler W and Rodemann HP. ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition. Cancer Biol Ther. 2014; 15(3):317-328.
72. Ebi H, Costa C, Faber AC, Nishtala M, Kotani H, Juric D, Della Pelle P, Song Y, Yano S, Mino-Kenudson M, Benes CH and Engelman JA. PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proc Natl Acad Sci U S A. 2013; 110(52):21124-21129.
73. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009; 69(2):565-572.
74. Li J and Zhou BP. Activation of beta-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer. 2011; 11:49.
75. Kawahara S, Otsuji Y, Nakamura M, Murakami M, Murate T, Matsunaga T, Kanoh H, Seishima M, Banno Y and Hara A. Sphingosine kinase 1 plays a role in the upregulation of CD44 expression through extracellular signal-regulated kinase signaling in human colon cancer cells. Anticancer Drugs. 2013; 24(5):473-483.
76. Gumbiner BM and Kim NG. The Hippo-YAP signaling pathway and contact inhibition of growth. J Cell Sci. 2014; 127(Pt 4):709-717.
77. Fan R, Kim NG and Gumbiner BM. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. Proc Natl Acad Sci U S A. 2013; 110(7):2569-2574.
78. Shaw RJ, Paez JG, Curto M, Yaktine A, Pruitt WM, Saotome I, O'Bryan JP, Gupta V, Ratner N, Der CJ, Jacks T and McClatchey AI. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev Cell. 2001; 1(1):63-72.
79. Surace EI, Haipek CA and Gutmann DH. Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function. Oncogene. 2004; 23(2):580-587.
80. Sher I, Hanemann CO, Karplus PA and Bretscher A. The tumor suppressor merlin controls growth in its open state, and phosphorylation converts it to a less-active more-closed state. Dev Cell. 2012; 22(4):703-705.
81. Zhou L and Hanemann CO. Merlin, a multi-suppressor from cell membrane to the nucleus. FEBS Lett. 2012; 586(10):1403-1408.
82. Chan EH, Nousiainen M, Chalamalasetty RB, Schafer A, Nigg EA and Sillje HH. The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene. 2005; 24(12):2076-2086.
83. Wu S, Huang J, Dong J and Pan D. hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell. 2003; 114(4):445-456.
84. Huang J, Wu S, Barrera J, Matthews K and Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell. 2005; 122(3):421-434.
85. Romano D, Nguyen LK, Matallanas D, Halasz M, Doherty C, Kholodenko BN and Kolch W. Protein interaction switches coordinate Raf-1 and MST2/Hippo signalling. Nat Cell Biol. 2014; 16(7):673-684.
86. Naor D, Wallach-Dayan SB, Zahalka MA and Sionov RV. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol. 2008; 18(4):260-267.
87. Ornelas IM, Silva TM, Fragel-Madeira L and Ventura AL. Inhibition of PI3K/Akt pathway impairs G2/M transition of cell cycle in late developing progenitors of the avian embryo retina. PLoS One. 2013; 8(1):e53517.
88. Li Y, Zhang P, Qiu F, Chen L, Miao C, Li J, Xiao W and Ma E. Inactivation of PI3K/Akt signaling mediates proliferation inhibition and G2/M phase arrest induced by andrographolide in human glioblastoma cells. Life Sci. 2012; 90(25-26):962-967.
89. Chiu CY, Kuo KK, Kuo TL, Lee KT and Cheng KH. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration. Mol Cancer Res. 2012; 10(3):415-427.
90. Yang S, Zhang L, Liu M, Chong R, Ding SJ, Chen Y and Dong J. CDK1 phosphorylation of YAP promotes mitotic defects and cell motility and is essential for neoplastic transformation. Cancer Res. 2013; 73(22):6722-6733.
91. Shie JL, Chen ZY, Fu M, Pestell RG and Tseng CC. Gutenriched Kruppel-like factor represses cyclin D1 promoter activity through Sp1 motif. Nucleic Acids Res. 2000; 28(15):2969-2976.
92. Ahn HJ, Kim G and Park KS. Ell3 stimulates proliferation, drug resistance, and cancer stem cell properties of breast cancer cells via a MEK/ERK-dependent signaling pathway. Biochem Biophys Res Commun. 2013; 437(4):557-564.
93. Lian I, Kim J, Okazawa H, Zhao J, Zhao B, Yu J, Chinnaiyan A, Israel MA, Goldstein LS, Abujarour R, Ding S and Guan KL. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev. 2010; 24(11):1106-1118.
94. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, Daidone MG, Dupont S, Basso G, Bicciato S and Piccolo S. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011; 147(4):759-772.
95. Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio R, Piazza S, Rosato A, Piccolo S and Del Sal G. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol. 2014; 16(4):357-366.